HUMAN · HPA v23 + CORNEAL ATLAS + DICE · 23 OCTOBER 2026

Which candidates survive the added normal-cell evidence?

589 previous CTAs → 435 still retained, 152 moved to Neither, and IL13/PAPPA excluded for published normal-cell protein. CT55 joins through cited reproductive and human tumor-recognition evidence: 436 retained.

CTA is a research eligibility decision, not established clinical safety. Unsafe alone supplies the forbidden background. Neither includes unresolved RNA/antibody findings and is neither a target nor proof of absence. CTAG2 remains Variable; FOXR2 awaits antibody review.